Evidence map›Paper›PMID 26226263›Full record

ArticlePloS one2015

Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein.

Valentine U Chukwuma, Mark D Hicar, Xuemin Chen, Katherine J Nicholas, Amanda Joyner, Spyros A Kalams, Gary Landucci, Donald N Forthal, Paul W Spearman, James E Crowe

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Valentine U ChukwumaDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America.
Mark D HicarDepartment of Pediatrics, Vanderbilt University, Nashville, Tennessee, United States of America.
Xuemin ChenDepartments of Pediatrics, Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Katherine J NicholasDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America.
Amanda JoynerDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America.
Spyros A KalamsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America; Department of Medicine, Vanderbilt University, Nashville, Tennessee, United States of America.
Gary LanducciDepartment of Medicine, University of California Irvine, Irvine, California, United States of America.
Donald N ForthalDepartment of Medicine, University of California Irvine, Irvine, California, United States of America.
Paul W SpearmanDepartments of Pediatrics, Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children's Healthcare of Atlanta, Atlanta, Georgia, United States of America.
James E CroweDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America; Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, United States of America; Vanderbilt Vaccine Center, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America.
Vanderbilt University · USUniversity of California, Irvine · USChildren's Healthcare of Atlanta · USEmory University · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
Clonal Analysis of the Human B Cell Response to HIVU01AI078407 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2008 to 2012
$3.9M
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infectionR01AI125119 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI HICAR, MARK DANIEL · 2016 to 2020
$2.0M
Viral and Cellular Determinants of HIV-1 AssemblyR01GM111027 · NIGMS · EMORY UNIVERSITY · PI SPEARMAN, PAUL W. · 2013 to 2019
$1.7M
Defining Neutralization Breadth in HIV+ Human SerumR01AI084834 · NIAID · EMORY UNIVERSITY · PI SPEARMAN, PAUL W. · 2009 to 2010
$775k
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)K08AI083078 · NIAID · VANDERBILT UNIVERSITY · PI HICAR, MARK DANIEL · 2009 to 2013
$639k
NCATS NIH HHS UL1 TR001414NIAID NIH HHS K08 AI 083078NIAID NIH HHS K08 AI083078NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI-054999NIAID NIH HHS P30 AI054999NIAID NIH HHS P30-AI50409NIAID NIH HHS R01 AI084834NIAID NIH HHS R01 AI125119NIAID NIH HHS U01 AI-078407NIAID NIH HHS U01 AI078407NIGMS NIH HHS R01 GM111027
6 · The paper itself

Abstract

The human antibody response against HIV-1 infection recognizes diverse antigenic subunits of the virion, and includes a high level of antibodies to the Gag protein. We report here the isolation and characterization of a subset of Gag-specific human monoclonal antibodies (mAbs) that were prevalent in the antibody repertoire of an HIV-infected individual. Several lineages of Gag-specifc mAbs were encoded by a single antibody heavy chain variable region, VH4-59, and a representative antibody from this group designated mAb 3E4 recognized a linear epitope on the globular head of the p17 subunit of Gag. We found no evidence that mAb 3E4 exhibited any function in laboratory studies aimed at elucidating the immunologic activity, including assays for neutralization, Ab-dependent cell-mediated virus inhibition, or enhanced T cell reactivity caused by Gag-3E4 complexes. The findings suggest this immunodominant epitope in Gag protein, which is associated with VH4-59 germline gene usage, may induce a high level of B cells that encode binding but non-functional antibodies that occupy significant repertoire space following HIV infection. The studies define an additional specific molecular mechanism in the immune distraction activity of the HIV virion.

Indexed as

Amino Acid SequenceAntibodies, MonoclonalB-LymphocytesGene Products, gagGenes, ImmunoglobulinHIV-1HIV AntibodiesHIV InfectionsHumansImmunodominant EpitopesMolecular Sequence DataNeutralization TestsT-LymphocytesVirionAntibodies, MonoclonalGene Products, gagHIV AntibodiesImmunodominant Epitopes

Identifiers

PMID26226263
PMCPMC4520566
OpenAlexW1633454671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.